Strong pipeline of highly differentiated products
The Lead Discovery Center GmbH (LDC) is working on a broad portfolio of drug discovery projects, small molecules and therapeutic antibodies. The indications include cancer and metabolic syndromes, neurodegenerative diseases, rare diseases, inflammatory disorders and infections, as well as other conditions with high, unmet clinical needs.
TARGET
HIT
LEAD
CANDIDATE
MARKET
TARGET
HIT
LEAD
CANDIDATE
CLINIC
target ID
target validation
assay development
screening
hit-to-lead conversion
lead-to-candidate conversion
PD
PH1
PH2
PH3
eCYCLOPHILINS
NET FORMATION INHIBITORS
GRK5
SLC6A15
GPR81
P2Y6
GLUT
NATA
GFAT
CDK12/13
NP-DERIVED ENZ. INHIBITORS
CYTOLYSIN
KRAS G12D
ASPA
WWC1/2
EPHRIN B2
GCN2
TTLL, CCP
PD DEMENTIA
HTRA1
SFRP1
NTNU1
IRE1
DRAXIN
RHO GEF
AUTOPHAGY
DEG S
LRKK2
P2X7
NANOCOMBAC
IL11-AB
FGFR4-AB
GLI2
FAO
APLK1
SPR
CMT1A
ERK-CASTing
CDK6
CCL22-AB
CAAI
MOFi
IMT
COVID
HELICASE INHIBITORS
ATGL
GABA
CD40/TRAF6
RdRp
GPR182
GBM-Combi
RiBi
ATUVECICLIB
Target 1
Target 2
Target 3
Target 4
Target 5
Target 6
Target 7
Target 8
Target 9
REWIND
PEARL RIVER BIO
QLi5 Therapeutics
CALTIC Therapeutics
KinSea Lead Discovery
